Bliss 76 study

Author: yztt

August undefined, 2024

WebJul 8, 2024 · BLISS-NEA (NCT01345253), like the BLISS-52 and -76 studies, was a 52-week, multicentre, randomised, double-blind, placebo-controlled study of the efficacy and safety of IV belimumab 10 mg/kg treatment among patients with clinically active SLE (defined as a SELENA-SLEDAI score ≥8 at screening) receiving ST located in China, … WebJan 9, 2024 · Besides physician-centered indices, the BLISS-52 and BLISS-76 trials (but not the Northeast Asia Trial) evaluated PROs relevant to HRQoL in SLE, including the generic Medical Outcomes Study 36-item Short Form Health Survey (SF-36 v2); secondary analyses were also performed using other generic questionnaires: the Functional …

Use of biologics in SLE: a review of the evidence from a clinical ...

WebThis analysis of studies BLISS-52 (GSK Study BEL110752), BLISS-76 (GSK Study BEL110751 ), BLISS-NEA (GSK Study113750 SC BEL112341), and EMBRACE (GSK Study BEL115471) was funded by GSK. Medical writing support was provided by Olivia Hill, MPharmacol, Fishawack Indicia Ltd., UK, part of Fishawack Health, and was funded by … WebAdults with SLE and a SELENA-SLEDAI score of either ≥8 (BLISS-NEA, BLISS-SC, EMBRACE) or ≥6 (BLISS-52, BLISS-76), with no selection or exclusion for any specific type of skin or vasculitic lesion at screening, … thundering surf

Bliss Summary & Analysis LitCharts

WebJan 24, 2024 · A post hoc analysis of the present (BLISS-SC) study and the pooled BLISS-52 and BLISS-76 studies was undertaken to compare only patients with SELENA–SLEDAI scores of ≥8 at baseline. In this analysis, … WebDec 12, 2006 · Official Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, … WebStudy design. BLISS-52 (n 865) and BLISS-76 (n 819) were multicenter, multinational, placebo-controlled trials in which patients with active SLE (SELENA–SLEDAI score 6 at screening) were randomized to standard therapy plus either placebo or belimumab at 1 or 10 mg/kg (24,25). In addition to active SLE, other inclusion criteria included auto- thundering surf beach haven

Systemic Lupus Erythematosus Disease Activity Score (SLE …

Human Genome Sciences, Inc. and GlaxoSmithKline Announce Topline 76 ...

WebMar 7, 2024 · Furie R, Petri M, Zamani O, et al. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30. CrossRef CAS Google Scholar WebMethods This post hoc integrated analysis (GSK Study 116559) included safety data from six randomised, placebo-controlled belimumab trials (BLISS-76, BLISS-52, BLISS-SC, North East Asia study, LBSL02, EMBRACE; n=4170). The BASE study provided additional safety data (n=4003). Efficacy data were from five of the trials. Older adults (≥65 years) … thundering stormray wowWebPost hoc analysis of the BLISS-76 population at study baseline. We performed a post hoc analysis of the BLISS-76 trial, assessing data from the baseline study visit, where patients were expected to have a high level of disease activity. We analysed the performance of the SLE-DAS cut-off value for moderate/severe disease activity (prospectively ... thundering surf water park discount coupons

"http://www.nephjc.com/news/bliss-ln " - Bliss 76 study

Bliss 76 study

Two-Year, Randomized, Controlled Trial of Belimumab in …

WebDec 2, 2011 · Study record managers: ... Lokhandwala T, Yue B, Coutinho AD, Bell CF. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. Lupus Sci Med. 2024 Feb;8(1):e000438. doi: 10.1136/lupus-2024-000438. WebObjective: To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. …

Did you know?

WebAug 30, 2011 · BLISS-76, the second phase III clinical trial of belimumab in SLE, was conducted primarily in North America and Europe. Treatment continued through week … Arthritis & Rheumatology, an official journal of the American College of … WebNational Center for Biotechnology Information

WebAug 29, 2024 · Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, BLISS-52 and -76 Study Groups. Improvements in health-related quality of life with Belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. WebApr 20, 2010 · BENLYSTA 10 mg/kg already met its primary efficacy endpoint at Week 52 in both BLISS-52 and BLISS-76, as announced in July and November 2009. At Week 76 in the BLISS-76 study, belimumab plus standard of care showed higher response rates compared with placebo plus standard of care as measured by the SLE Responder Index; however, …

WebThis analysis of studies BLISS-52 (GSK Study BEL110752), BLISS-76 (GSK Study BEL110751 ), BLISS-NEA (GSK Study113750 SC BEL112341), and EMBRACE (GSK … WebJul 25, 2010 · Under BLISS-76, 819 patients at 133 clinical sites in 19 countries were enrolled and randomised. The BLISS-76 study results, unveiled in October 2010, showed that Benlysta demonstrated higher response rates compared to a placebo. It was also found that the drug continued to be well tolerated and that adverse events rates remained …

WebJan 24, 2024 · Significant reductions in severe flare were observed with belimumab 10 mg/kg IV over 52 weeks in the BLISS-52 study 18 and with belimumab 1 mg/kg IV over 76 weeks in the BLISS-76 study 17. Onset …

WebBLISS-52 (52 weeks) and BLISS-76 (76 weeks) were parallel-group studies investigating the efficacy and safety of belimumab administered by intravenous infusion in adult patients with active SLE.1 2 The study designs and methods have been described previously, and the primary endpoint for both studies was response rate at week 52, assessed by ... thundering surf lbi njWebJan 19, 2007 · Brief Summary: The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered … thundering surf njWebMay 21, 2013 · A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. thundering tauWebin BLISS-76. BLISS = Belimumab International SLE Study; CI = confidence interval; HR = hazard ratio; SELENA-SLEDAI = Safety of Estrogens in Lupus Erythematosus: National … thundering surf waterparkWebPost hoc analyses involving patients in BLISS-52 and BLISS-76 who had proteinuria at baseline showed decreased proteinuria and a lower … thundering surf water park njWebFeb 16, 2024 · The multicenter extension study involved patients who had completed 72 weeks of treatment in the BLISS-76 Phase 3 trial (NCT00410384), to further test its safety and effectiveness when used in combination with standard of care.After seven years of treatment, data shows that most patients had no new organs affected by the disease. thundering thesaurusWebBliss Summary. Thirty-year old Bertha Young is overcome by a feeling of excitement, or “bliss,” while preparing to throw a dinner party for a group of her friends. Returning home … thundering taxis